Singleron
Singleron Biotechnologies provides single cell multi-omics solutions, including automated processing, tissue dissociation, reagents, and bioinformatics tools to advance precision medicine.
Classification
Profile
Funding
Funding details not yet available.
Compliance
Makes single cell multi-omics analysis accessible and understandable to advance precision medicine through automated processing, reagents, and bioinformatics tools.
Researchers, clinicians, and pharmaceutical partners requiring single-cell analysis services or kits.
Sales of sequencing kits and fees for comprehensive single-cell analysis services including consultation, processing, and data analysis.
Direct sales through global offices in Germany, Singapore, North America, and China, plus a downloadable technical documentation portal.
Pharma partners for service projects and global laboratory infrastructure supporting international operations.
R&D for patented technologies, global laboratory operations, logistics for sample handling, and technical support staff.
Proprietary technology covering the entire process from tissue dissociation to bioinformatics, along with manufacturing facilities and labs in Cologne and Singapore.
Developing automated single cell processing and tissue dissociation solutions, and providing reagents and bioinformatics tools.
Service-led with project consultation, handling fresh or frozen samples shipped directly by clients for end-to-end analysis.
Competes in the global single-cell sequencing market with patented solutions; differentiates through full-spectrum end-to-end service coverage.
Making complex single cell multi-omics analysis accessible and understandable for the advancement of precision medicine.
- Launch a “Clinical Adoption Program” - Offer pilot studies, data-sharing agreements, and co-branding with hospital networks to accelerate
- The BMC aligns with industry‑standard models used by leading genomics firms (e.g., 10x Genomics, Illumina), confirming the relevance of the identified blocks.
- The inclusion of FDA Class II clearance as a core differentiator is supported by the company’s news releases and regulatory filings, providing a concrete competitive moat.
Team details not yet available.
No investors recorded yet.